This Genital Warts (Condyloma Acuminatum)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Genital Warts (Condyloma Acuminatum), historical and forecasted epidemiology as well as the Genital Warts (Condyloma Acuminatum) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
GWs can appear on the penis, vulva, vagina, cervix, groin, or thigh within weeks or months after sexual contact with an infected person. Potentially cancer-causing HPV strains are spread by sexual intercourse, anal sex, and oral sex.
Genital Warts Disease Understanding
Genital warts (also known as anogenital warts, condylomata acuminata, condylomas) are benign proliferative lesions caused by human papillomavirus (HPV) types 6 and 11, which are found in >95% of lesions. Genital warts (GWs) are transmitted by having sexual contact with someone who already has them and may be found on the outside of genitals. Some types, which cause cancer, result in the growth of lesions on a woman's cervix. It is possible to get genital warts, HPV infection, even if they are not visible. Besides, they look like flesh-colored bumps that have a cauliflower-like appearance, and are usually flat, papular, or pedunculated growths on the genital mucosa, occurring in clusters.GWs can appear on the penis, vulva, vagina, cervix, groin, or thigh within weeks or months after sexual contact with an infected person. Potentially cancer-causing HPV strains are spread by sexual intercourse, anal sex, and oral sex.
Genital Warts Diagnosis
Genital warts are often diagnosed by appearance. Sometimes a biopsy might be necessary based on indications such as atypical appearance, HIV positive persons, pigmented warts, poor response to the treatment and unclear diagnosis. Clinical diagnosis of GW is based on the appearance of warts, whereas histopathological diagnosis is not routinely indicated. Nucleic Acid Amplification Test for HPV DNA is also recommended. Accurate diagnosis is an essential first step in the treatment of GWs. They can be flat, dome-shaped, keratotic, pedunculated, and cauliflower-shaped; they may occur singularly, in clusters, or as plaques. Understanding the morphological presentation of these lesions is essential to accurate diagnosis of EGWs and their differentiation from other lesions that mimic them. However, warts are not exclusive to external genital tissues. Sexual exposure can be associated with warts in the urethra and at the meatus, cervix, vagina, anus, and oral cavity. Cervical warts, however, require clinicians to rule out high-grade dysplasia using Papanicolaou (Pap) tests before treatment.Genital Warts Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident cases of Genital Warts, Gender-specific Incident Cases of Genital Warts, Age-specific Incident Cases of Genital Warts, Anatomical Location of Genital Warts in Incident Population in the 7MM+China covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2019 to 2032.Genital Warts Detailed Epidemiology Segmentation
- In the assessment done by the publisher, the estimated total incident cases of GWs in the 7MM+China were 1,392,836 in 2021.
- The highest incident cases of GWs were accounted by the US in 2021 (545,316 cases), which are expected to show a rise in the future.
- Among the European countries, Germany had the highest incident population of GWs with 77,210 cases, followed by France, which had incident population of 55,798 in 2021. On the other hand, Spain had the lowest incident population (42,588 cases).
- Japan had 38,043 incident cases for GWs in 2021, accounting for approximately 3% in 7MM+China.
Scope of the Report
- The report covers the descriptive overview of Genital Warts, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM+China historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
- The report assesses the disease risk and burden of Genital Warts.
- The report helps to recognize the growth opportunities in the 7MM+China with respect to the patient population.
Report Highlights
- 11-Year Forecast of Genital Warts
- 7MM+China Coverage
- Incident Cases of Genital Warts
- Gender-specific Incident Cases of Genital Warts
- Age-specific Incident Cases of Genital Warts
- Anatomical Location of Genital Warts in Incident Population
Key Questions Answered
- What are the disease risk and burden of Genital Warts?
- What is the historical Genital Warts patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan and China?
- What would be the forecasted patient pool of Genital Warts at the 7MM+China level?
- What will be the growth opportunities across the 7MM+China with respect to the patient population pertaining to Genital Warts?
- Out of the above-mentioned countries, which country would have the highest incident population of Genital Warts during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM+China during the forecast period (2022-2032)?
Reasons to Buy
The Genital Warts report will allow the user to -- Develop business strategies by understanding the trends shaping and driving the 7MM+China Genital Warts epidemiology forecast.
- The Genital Warts epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Genital Warts epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Patient Segmentation based on Gender
- Patient Segmentation based on Age
- Patient Segmentation based on Anatomical Location of Genital Warts
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
- China
Table of Contents
1. Key Insights2. Report Introduction
3. Genital Warts Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Genital Warts by Countries in 2019
3.2. Patient Share (%) Distribution of Genital Warts by Countries in 2032
4. Genital Warts Epidemiology: Future Perspective
5. Executive Summary of Genital Warts
6. Disease Background and Overview: Genital Warts
6.1. Introduction
6.2. Natural History
6.3. Causes and Risks
6.4. Symptoms
6.5. Pathophysiology
6.6. Clinical Presentation
6.7. Complications of Untreated HVP Infection
6.8. Diagnosis
6.8.1. Pap Test
6.8.2. HPV test
6.8.3. Newer Techniques
6.8.4. Diagnostic Guidelines
7. Treatment and Management
7.1. Chemical Treatment (Self-administered)
7.2. Chemical Treatment (Physician-applied)
7.3. Other Treatments
7.4. Ablative Treatment
7.5. Preventive Treatment
7.6. Therapies Not Recommended
7.6.1. Enhancing the Efficacy of Imiquimod
7.7. Adverse Effects of Treatment
7.8. Selection of Treatment
7.9. Special Management Issues
8. Vaccines
8.1. Gardasil: Merck
8.2. Cervarix: GlaxoSmithKline
8.3. Comparison
8.4. Differences
9. Guidelines
9.1. Anogenital Warts Treatment Guidelines: CDC
9.2. European Guideline for the Management of Anogenital Warts
9.3. Guidance on HPV vaccination in EU countries: Focus on boys, people living with HIV, and 9-valent HPV vaccine introduction: ECDC
9.4. Guidelines for the Management of Anogenital Warts in China
10. Epidemiology and Patient Population
10.1. Key Findings
10.2. Methodology of Epidemiology
10.3. Assumptions and Rationale: 7MM+China
10.3.1. United States
10.3.2. EU5 Countries
10.3.3. Japan
10.3.4. China
10.4. Total Incidence of GWs in the 7MM+China
10.5. The United States
10.5.1. Incident Cases of GWs in the United States
10.5.2. Gender Specific Incident Cases of GWs in the United States
10.5.3. Age Specific Incident Cases of GWs in the United States
10.5.4. Anatomical Location of GWs in Incident Population in the United States
10.6. Major Five European Countries
10.6.1. Incident cases of GWs in the EU-5
10.6.2. Gender Specific Incident Cases of GWs in the EU-5
10.6.3. Age Specific Incident Cases of GWs in the EU5
10.6.4. Anatomical Location of GWs in Incident Population in the EU-5
10.7. Japan
10.7.1. Incidence Cases of GWs in Japan
10.7.2. Gender Specific Incident Cases of GWs in Japan
10.7.3. Age Specific Incident Cases of GWs in Japan
10.7.4. Anatomical Location of GWs in Incidence Population in Japan
10.8. China
10.8.1. Incidence Cases of GWs in China
10.8.2. Gender Specific Incident Cases of GWs in China
10.8.3. Age Specific Incident Cases of GWs in China
10.8.4. Anatomical Location of GWs in Incident Population in China
11. Patient Journey
12. Appendix
12.1. Bibliography
12.2. List of Abbreviations
12.3. Report Methodology
13. Publisher Capabilities
14. Disclaimer
15. About the Publisher
List of Tables
Table 1: Summary of Genital Warts Epidemiology (2019-2032)
Table 2: Low-risk HPV versus High-risk HPV
Table 3: Treatment Modalities
Table 4: Treatments and their Advantages
Table 5: Enhancing the efficacy of imiquimod
Table 6: Gardasil versus Cervarix
Table 7: Total Incident Population of GWs in 7MM+China (2019-2032)
Table 8: Incident cases of GWs in the United States (2019-2032)
Table 9: Gender Specific Diagnosed Cases of GWs in the United States (2019-2032)
Table 10: Age Specific Diagnosed Cases of GWs in the United States (2019-2032)
Table 11: Anatomical Location of GWs in Incident Population in the United States (2019-2032)
Table 12: Incident Cases of GWs in the EU-5 (2019-2032)
Table 13: Gender Specific Incident Cases of GWs in the EU-5 (2019-2032)
Table 14: Age Specific Incident Cases of GWs in the EU-5 (2019-2032)
Table 15: Age Specific Incident of GWs in Incident Population in the EU-5 (2019-2032)
Table 16: Incident Cases of GWs in Japan (2019-2032)
Table 17: Gender Specific Incident Cases of GWs in Japan (2019-2032)
Table 18: Age Specific Incident Cases of GWs in Japan (2019-2032)
Table 19: Anatomical Location of GWs in Incident Population in Japan (2019-2032)
Table 20: Incident Cases of GWs in China (2019-2032)
Table 21: Gender Specific Incident Cases of GWs in China (2019-2032)
Table 22: Age Specific Incident Cases of GWs in China (2019-2032)
Table 23: Anatomical Location of GWs in Incident Population in China (2019-2032)
Table 24: List of abbreviationsList of Figures
Figure 1: Different Types of Warts
Figure 2: HPV Structure and Function
Figure 3: HPV Structure and Function
Figure 4: Infection by HPV
Figure 5: Checklist for Initial Consultation
Figure 6: Checklist for providing Treatment
Figure 7: Treatment Algorithm
Figure 8: Newer Simplified Treatment Algorithm
Figure 9: Algorithm for Treatment Selection
Figure 10: Algorithm for Treatment Selection in Pregnant Patients
Figure 11: Total Incident Population of GWs in 7MM+China (2019-2032)
Figure 12: Incident cases of GWs in the United States (2019-2032)
Figure 13: Gender Specific Incident Cases of GWs in the United States (2019-2032)
Figure 14: Age Specific Incident Cases of GWs in the United States (2019-2032)
Figure 15: Anatomical Location of GWs in Incident Population in the United States (2019-2032)
Figure 16: Incident Cases of GWs in the EU-5 (2019-2032)
Figure 17: Gender Specific Incident Cases of GWs in the EU-5 (2019-2032)
Figure 18: Age Specific Incident Cases of GWs in the EU5 (2019-2032)
Figure 19: Anatomical Location of GWs in Incident Population in the EU5 (2019-2032)
Figure 20: Incident Cases of GWs in Japan (2019-2032)
Figure 21: Gender Specific Incident Cases of GWs in Japan (2019-2032)
Figure 22: Age Specific Incident Cases of GWs in Japan (2019-2032)
Figure 23: Anatomical Location of GWs in Incidence Population in Japan (2019-2032)
Figure 24: Incidence Cases of GWs in China (2019-2032)
Figure 25: Gender Specific Incident Cases of GWs in China (2019-2032)
Figure 26: Age Specific Incident Cases of GWs in China (2019-2032)
Figure 27: Anatomical Location of GWs in Incident Population in China (2019-2032)
Figure 28: Patient Journey
